S32. Therapeutic Potential of Nociceptin/Orphanin Fq (NOP) Receptor Antagonists in a Rodent Model of Traumatic Stress

      Current FDA-approved pharmacotherapies for the treatment of post-traumatic stress disorder (PTSD) are limited in number and efficacy. Recent evidence implicates the nociceptin/orphanin FQ (NOP) receptor system in PTSD. Therefore, NOP antagonists may have therapeutic potential for the treatment of PTSD. Here, we evaluate the efficacy of NOP antagonists to remediate the effects of traumatic stress exposure using preclinical rodent models of traumatic stress exposure and conditioned fear.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect